查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1837481

骨關節炎疼痛治療市場按產品類型、給藥途徑、通路、最終用戶、患者年齡層和疾病嚴重程度分類－2025-2032年全球預測

Osteoarthritis Pain Drug Market by Product Type, Route Of Administration, Distribution Channel, End User, Patient Age Group, Disease Severity - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，骨關節炎止痛藥市場將成長至 143.3 億美元，複合年成長率為 6.67%。

主要市場統計數據
基準年 2024 85.4億美元
預計年份：2025年 91.2億美元
預測年份：2032年 143.3億美元
複合年成長率 (%) 6.67%

本書策略性地介紹了不斷發展的骨關節炎疼痛治療領域，重點闡述了臨床要務、患者多樣性以及相關人員的實用創新路徑。

由於患者需求各異、慢性疼痛病程複雜，以及不同年齡層和疾病嚴重程度的患者功能受損程度不同，骨關節炎仍是一個複雜的臨床挑戰。臨床醫生和支付方越來越傾向於尋求能夠快速緩解症狀、長期使用安全且能顯著改善活動能力和生活品質的治療方法。近期的臨床創新主要集中在完善現有的藥物分類，並探索新的機制，以解決在持久控制疼痛和延緩疾病進展方面存在的持續性不足。

在此背景下，製造商正在調整研發重點，著重於差異化的給藥方式、提升老年族群的安全性，以及開發適合門診和居家照護模式的解決方案。同時，醫療系統和專科診所也在尋求能夠將產品性能與實際療效聯繫起來的證據。本次研究將深入探討影響骨關節炎疼痛治療商業性和臨床格局的治療層級、給藥途徑趨勢、分銷動態以及病患細分。

骨關節炎疼痛領域在治療方法選擇、給藥方式和證據要求方面正在經歷重大的科學、臨床和商業性變革。

受科學進步、支付方期望轉變以及技術賦能的醫療模式的推動，骨關節炎的治療格局正在發生顯著變化。生物製劑和標靶小分子藥物正在重塑治療格局，而傳統藥物則不斷提供能夠提高耐受性和依從性的治療選擇。同時，數位健康平台和遠端監測的出現使得對疼痛軌跡和功能改善的評估更加精準，有助於制定療效評估方案和個人化治療流程。

在商業性，製造商正透過策略聯盟、專業合作和差異化市場策略來因應這一轉變，優先發展高價值的臨床細分市場。隨著監管機構越來越依賴真實世界證據和加速核准，哪些候選藥物能夠獲得持續應用將取決於它們能否產生可靠的核准後數據。此外，無菌注射劑生產和先進外用製劑技術的進步正在改變臨床醫生選擇治療方法的方式，從診所到居家醫療，這使得圍繞實際給藥限制進行研發變得更加重要。

分析截至 2025 年的關稅措施如何改變了骨關節炎治療藥物的供應鏈、生產佈局和採購重點。

到2025年，累積貿易措施和不斷變化的關稅政策對骨關節炎治療藥物供應鏈、生產經濟和籌資策略產生了多方面的影響。對關鍵中間體和成品進口徵收更高的關稅，加劇了依賴跨境原料藥和輔料流通的企業的投入成本波動。因此，製造商和合約研發受託製造機構正在加快供應商多元化，擴大本地灌裝能力，並重新審視長期採購協議，以降低關稅引發的成本上漲風險。

除了成本之外，關稅也在影響企業關於散裝無菌製劑和特種製劑製造地地點的策略決策。注射劑需要嚴格的無菌製程和高效的低溫運輸物流，因此企業越來越傾向於在國內或鄰近地區製造地，以減少跨境的複雜性。相反，常溫保存的外用和口服藥物則透過庫存管理和選擇性採購，獲得了更大的靈活性，以應對關稅相關的物流變化。支付方和醫院採購團隊正在加強對總到岸成本和供應韌性的審查，促使製造商提供更透明的供應鏈保證和緊急時應對計畫。總而言之，2025年的關稅趨勢將強化韌性作為核心商業差異化因素的重要性，迫使企業調整製造地、籌資策略和定價模式，以適應不斷變化的貿易狀況。

可操作的細分洞察，揭示產品類型、給藥途徑、通路動態和患者群體如何系統性地決定臨床定位和商業策略。

基於主導市場的骨關節炎治療生態系統分析揭示了不同治療層級和給藥途徑的產品策略所體現的獨特臨床和商業性行為。按產品類型分類，Cyclooxygenase-2抑制劑和非類固醇消炎劑是全身症狀控制的基石，而皮質類固醇仍然是急性虛弱管理的首選藥物，緩釋製劑在長期症狀控制中發揮著重要作用，粘稠補充劑則佔據了關節內給藥的特定領域，為尋求局部動態支持的患者提供服務。給藥途徑影響臨床定位和應用動態，注射劑又細分為關節內注射（主要用於關節治療）和肌肉注射（用於特定護理管道）；口服劑型分為膠囊、液體和片劑，以滿足患者的依從性和劑量需求；局部療法則以乳膏、凝膠和貼劑的形式提供，以滿足其他疾病的患者或併發症的患者的需求。

分銷管道的選擇反映了購買行為和臨床診療需求，既要兼顧醫院藥房的急性護理採購，又要兼顧零售藥房的慢性病管理，同時還要拓展線上藥房管道，以促進直接面向患者的銷售和依從性管理項目。終端使用者細分揭示了不同的期望，例如診所傾向於快速有效且與手術相容的藥物，家庭醫療保健優先考慮長期治療的易用性和安全性，而醫院則優先考慮治療嚴重的療效和供應可靠性。不同年齡層（18歲以下青少年、18-64歲成人和65歲及以上老年人）的因素決定了製劑和劑量方面的優先順序，其中老年人群需要更加關注合併症相互作用和多重用藥問題。最後，疾病嚴重程度（輕度、中度和重度）與治療強度和劑量直接相關，輕度患者需要局部或口服維持治療，而重症患者則需要注射或聯合治療。這些細分為優先考慮研發投資、標籤定位和市場推廣策略提供了一個多維框架。

區域戰略資訊闡述了美洲、歐洲、中東和非洲以及亞太地區的動態將如何決定市場准入、應用和生產優先事項。

區域動態對臨床應用、監管方式和供應鏈設計的影響在各大區域之間存在顯著差異。在美洲，醫療系統和私人支付方對成本效益和持續功能獲益證據的重視，加速了人們對能夠顯著改善行動能力並減少急診醫療資源利用的治療方法的興趣。北美強大的生產能力和成熟的專業醫療基礎設施支持了先進注射劑和聯合治療通訊協定的快速應用，而採購方面的嚴格審查則促使人們期望獲得透明的供應保障。

在歐洲、中東和非洲，監管環境和報銷機制的多樣性要求企業制定有針對性的打入市場策略，使臨床提案主張與當地的衛生技術評估框架和支付方的優先事項保持一致。歐洲、中東和非洲的某些市場也蘊藏著巨大的機遇，可以與應對人口老化的公共衛生措施相結合，從而推動對更安全的慢性病治療和社區醫療服務模式的需求。在亞太地區，人口結構的變化、專科診所的快速擴張以及靈活的契約製造行業正在推動新型製劑的快速上市，但報銷細分和准入差異仍然是限制因素。在整個全部區域，真實世界數據的互通性和本地生產投資仍然是決定企業優先推出產品和擴大生產線規模的關鍵因素。

公司層面的洞察，展現如何運用產品創新、夥伴關係和製造韌性來確保商業性和臨床差異化。

骨關節炎疼痛領域的主要企業正在採取不同但互補的策略，以保持競爭力並實現臨床差異化。許多企業正在投資研發新一代製劑，以增強藥物對關節的標靶作用，同時降低全身暴露，進而提高老年患者和併發症患者的耐受性。生物技術開發商、專科藥房和分銷合作夥伴之間的策略聯盟正被用於加速藥物研發、提高患者依從性，並建立能夠收集真實世界療效數據的長期患者支援服務。

在營運方面，各公司正在加強無菌生產能力，降低供應鏈風險，並實現地域多元化，以更好地適應區域採購趨勢。在商業性，各公司越來越重視透過衛生經濟模型和結果研究來向醫療保健採購方和支付方展示價值。那些能夠兼具臨床差異化、供應鏈透明可靠以及清晰展現實際應用效果路徑的公司，在臨床和專業配藥領域更具優勢。

針對製造商和相關人員可採取的行動建議，旨在增強骨關節炎治療的供應韌性、臨床相關性以及與支付方目標一致的價值證明。

產業領導者應採取多管齊下的策略，以保持發展勢頭並應對短期挑戰，同時建立長期競爭優勢。首先，優先考慮供應商多元化，並投資於區域填充和無菌生產能力，以降低跨境貿易波動帶來的風險，並滿足醫院對供應韌性的期望。其次，透過專注於開發能夠提高老年人用藥安全性、便於門診給藥並減輕居家看護者負擔的製劑，使產品開發與實際臨床需求相符。第三，加快產生將藥物療效與功能性結果和醫療資源利用聯繫起來的真實世界證據，以支持與支付方的溝通以及基於結果的合約簽訂。

此外，企業應拓展數位互動和病患支援基礎設施，以提高用藥依從性，並持續收集療效數據，從而指導產品迭代改進。商業策略應包括有針對性的通路最佳化，平衡醫院藥局的滲透率與零售藥局和線上藥局的覆蓋範圍，確保分銷能同時滿足急性治療需求和慢性維持治療需求。最後，應將情境規劃納入採購和定價策略，以便在不影響臨床供應或策略上市時間表的前提下，應對關稅變化、供應中斷或報銷政策調整。

對混合方法研究途徑進行清晰描述，該方法整合了主要臨床發現、次要資訊和基於情境的分析，以確保得出嚴謹且具有可操作性的研究結果。

本研究採用混合方法，結合一手研究、相關人員參與、有針對性的二手資訊和定量綜合分析，得出可靠且可操作的結論。一手研究包括對風濕病學家、骨科醫生、支付方、醫院採購人員和高級商業主管進行結構化訪談，以了解治療偏好、藥品目錄動態和採購促進因素。二手資訊來自同行評審的臨床文獻、監管出版物、公共臨床實驗室註冊庫、專利申請和已驗證的供應鏈資料庫，以驗證治療趨勢、研發管線活動和生產佈局。

分析方法包括細分市場分析、情境分析（用於探討供應中斷和關稅的影響）以及交叉驗證技術（用於將觀察到的採購行為與定性輸入資料進行比對）。品質保證措施包括專家評審小組和調查方法審核，以確保各主題研究結果的一致性。這些方法將臨床需求、分銷實際情況和商業性考量連結起來，從而建立依證，為產品開發和市場准入提供切實可行的建議。

總結回顧：相關人員必須整合臨床、商業性和營運方面的必要因素，才能在不斷發展的骨關節炎治療領域中取得成功。

總之，骨關節炎疼痛治療領域的格局正因臨床創新、不斷演變的分銷管道以及供應鏈的迫切需求而再形成，這些因素共同定義了新的商業性和臨床成功閾值。有效的策略取決於透過標靶製劑和給藥機制提供差異化的臨床價值，同時展現對支付方和臨床醫生至關重要的真正功能性獲益。在地化生產和透明的採購流程所體現的供應韌性，已成為商業性信譽中不可或缺的要素。

將研發組合與以患者為中心的治療結果相結合、投資於循證醫學研究並採用靈活的生產和分銷模式的相關人員，將更有能力應對不斷變化的市場環境。透過將這些策略重點納入研發和商業化計劃，企業可以更好地滿足臨床醫生和患者的多元化需求，同時在動態的監管和商業環境中保持營運靈活性。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 快速實施皮下單株抗NGF療法可提高中重度骨關節炎疼痛緩解的持久性
  • 一種緩釋型關節內水凝膠製劑的出現，可將膝關節炎的治療效果延長至12週以上。
  • 由於患者偏好採用替代療法來治療慢性骨關節炎疼痛，低仿單標示外口服大麻素的非適應症使用正在增加。
  • 將穿戴式關節運動感測器與個人化疼痛管理應用程式結合的數位健康平台正在獲得越來越多的投資。
  • 為了確保生物安全性並降低成本，抗TNF療法在骨關節炎發炎治療中生物相似藥的研發越來越受歡迎。
  • 進行一項真實世界證據研究，以評估非鴉片類鎮痛藥在不同骨關節炎患者群體中的相對療效
  • 擴大非類固醇抗發炎藥物與輔助性神經生長因子抑制劑的聯合治療，以最大限度地降低胃腸道和心血管風險。

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依產品類型分類的骨關節炎疼痛治療市場

  • 皮質類固醇
  • Cyclooxygenase-2抑制劑
  • 非類固醇消炎劑
  • 用於緩解症狀的促效劑
  • 黏稠補充劑

9. 依給藥途徑分類的骨關節炎疼痛治療市場

  • 注射
    • 關節內
    • 肌肉內注射
  • 口服
    • 膠囊
    • 液體
    • 藥片
  • 局部的
    • 奶油
    • 凝膠
    • 修補

第10章 骨關節炎疼痛治療市場（依通路分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章 骨關節炎疼痛治療市場（依最終用戶分類）

  • 診所
  • 家庭醫療保健
  • 醫院

第12章 依患者年齡層分類的骨關節炎疼痛治療市場

  • 18歲以下的青少年
  • 18-64歲的成年人
  • 65歲及以上的老年人

第13章 依疾病嚴重程度分類的骨關節炎疼痛治療市場

  • 溫和的
  • 緩和
  • 嚴重

第14章 各地區骨關節炎疼痛治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 骨關節炎疼痛治療市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國骨關節炎疼痛治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Pfizer Inc.
    • Novartis AG
    • Bayer AG
    • Johnson & Johnson
    • Sanofi SA
    • GlaxoSmithKline plc
    • Viatris Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Sandoz International GmbH
    • Perrigo Company plc
Product Code: MRR-0376B2CAAFEB

The Osteoarthritis Pain Drug Market is projected to grow by USD 14.33 billion at a CAGR of 6.67% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 8.54 billion
Estimated Year [2025] USD 9.12 billion
Forecast Year [2032] USD 14.33 billion
CAGR (%) 6.67%

A strategic introduction to the evolving osteoarthritis pain drug environment that frames clinical imperatives, patient diversity, and practical innovation pathways for stakeholders

Osteoarthritis remains a complex clinical challenge driven by heterogeneous patient needs, chronic pain trajectories, and variable functional impacts across age groups and disease severity. Clinicians and payers increasingly seek therapies that balance rapid symptom relief, safety for long-term use, and demonstrable effects on mobility and quality of life. Recent clinical innovation has focused on refining existing pharmacologic classes and exploring novel mechanisms to address persistent gaps in durable pain control and disease progression.

Against this backdrop, manufacturers are adapting development priorities to emphasize differentiated delivery formats, improved safety profiles for older adults, and solutions compatible with ambulatory and home-based care models. Concurrently, health systems and specialty clinics are demanding evidence that links product performance to real-world functional outcomes. This introduction sets the stage for a detailed examination of therapeutic classes, route-of-administration trends, distribution dynamics, and patient segmentation that together shape the commercial and clinical contours of the osteoarthritis pain drug space.

Transformative scientific, clinical, and commercial shifts reshaping therapeutic choices, delivery formats, and evidence expectations across the osteoarthritis pain landscape

The osteoarthritis drug landscape is undergoing transformative shifts driven by scientific advances, shifting payer expectations, and technology-enabled care models. Biologic approaches and targeted small molecules are redefining therapeutic possibilities, while formulation science continues to deliver options that improve tolerability and adherence. At the same time, the emergence of digital health platforms and remote monitoring is enabling more precise assessment of pain trajectories and functional improvement, which in turn supports outcomes-based contracting and personalized treatment algorithms.

Commercially, manufacturers are responding to these shifts through strategic alliances, specialty partnerships, and differentiated go-to-market strategies that prioritize high-value clinical niches. As regulatory pathways adapt to accommodate real-world evidence and accelerated approvals, the ability to generate robust post-authorization data will determine which candidates achieve sustainable uptake. In addition, ongoing improvements in sterile injectable manufacturing and advanced topical formulations are changing how clinicians select therapies across care settings, from clinics to home-based care, which reinforces the importance of aligning development with practical delivery constraints.

An analytical view of how tariff developments through 2025 have reshaped supply chains, manufacturing footprints, and procurement priorities across osteoarthritis therapeutics

The cumulative trade measures and tariff policy shifts introduced through 2025 have imparted a multifaceted impact on supply chains, manufacturing economics, and procurement strategies for osteoarthritis therapeutics. Increased duties on key intermediates and finished imports have elevated input cost volatility for companies reliant on cross-border API and excipient flows. As a direct consequence, manufacturers and contract development and manufacturing organizations have accelerated supplier diversification, expanded local fill-finish capacity, and reevaluated long-term sourcing agreements to mitigate exposure to tariff-driven cost escalation.

Beyond cost considerations, tariffs have influenced strategic decisions around where to locate high-volume sterile manufacturing versus specialized formulation work. Injectable therapies, which require stringent sterile processes and validated cold-chain logistics, have seen heightened attention to domestic or regionally proximate production to reduce cross-border complexity. Conversely, topical and oral formulations with longer shelf stability have provided more flexibility to absorb tariff-related logistics changes through inventory management and selective sourcing. Payers and hospital procurement teams have responded by intensifying scrutiny of total landed cost and supply resilience, prompting manufacturers to present more transparent supply chain assurances and contingency plans. In sum, tariff dynamics through 2025 have reinforced resilience as a core commercial differentiator, compelling companies to align manufacturing footprint, procurement strategies, and pricing models with evolving trade realities.

Actionable segmentation insights revealing how product types, administration routes, channel dynamics, and patient cohorts systematically determine clinical positioning and commercial strategy

A segmentation-led understanding of the osteoarthritis therapeutic ecosystem reveals distinct clinical and commercial behaviors that inform product strategy across therapeutic classes and delivery routes. In terms of product type, corticosteroids continue to be relied upon for acute flare management while cyclooxygenase 2 inhibitors and nonsteroidal anti-inflammatory drugs remain foundational for systemic symptom control, symptomatic slow-acting drugs serve niche roles in long-term symptom modulation, and viscosupplements occupy a specific intra-articular niche for patients seeking localized biomechanical support. Route of administration shapes clinical positioning and adoption dynamics, with injectable approaches subdividing into intra-articular options favored for targeted joint therapy and intramuscular formats used in specific care pathways, oral administration dividing into capsules, liquid formulations, and tablets to match adherence and dosing needs, and topical therapies offered as creams, gels, and patches that cater to safety-conscious or comorbid populations.

Distribution channel choices reflect purchasing behavior and care setting needs, balancing hospital pharmacy procurement for acute procedural use with retail pharmacy access for chronic management and growing online pharmacy channels that facilitate direct-to-patient fulfillment and adherence programs. End-user segmentation shows distinct expectations across clinics that favor rapid-onset, procedure-compatible options; home healthcare that prioritizes ease-of-use and safety for extended treatment; and hospitals that emphasize efficacy in severe presentations and supply reliability. Age-based considerations-adolescents under 18, adults 18 to 64, and elderly 65 plus-drive formulation and dosing priorities, with the elderly cohort demanding heightened attention to comorbidity interactions and polypharmacy. Finally, disease severity bands of mild, moderate, and severe map directly to therapeutic intensity and delivery format, where milder presentations trend toward topical and oral maintenance therapies and more severe disease necessitates injectable or combined modality strategies. Together, these segmentation dimensions provide a multidimensional framework to prioritize development investments, label positioning, and market access tactics.

Regional strategic intelligence describing how Americas, Europe Middle East & Africa, and Asia-Pacific dynamics determine access, adoption, and manufacturing priorities

Regional dynamics are influencing clinical adoption, regulatory approaches, and supply chain design in markedly different ways across major geographies. In the Americas, health systems and private payers are focusing on cost-effectiveness and evidence of durable functional benefit, which accelerates interest in therapies that can demonstrate measurable improvements in mobility and reduced utilization of acute care resources. North American manufacturing capacity and a mature specialty care infrastructure support rapid adoption of advanced injectables and combination treatment protocols, while procurement scrutiny drives expectations for transparent supply assurances.

In Europe, Middle East & Africa, regulatory heterogeneity and diverse reimbursement mechanisms require targeted market access strategies that align clinical value propositions with local HTA frameworks and payer priorities. The EMEA region also presents significant opportunities to align public health initiatives with aging populations in certain markets, creating demand for safer chronic-use therapies and community-delivered care models. In the Asia-Pacific region, demographic shifts, rapid expansion of specialty clinics, and an agile contract manufacturing sector are fostering faster uptake of novel formulations, although fragmented reimbursement and variable access remain constraints. Across regions, interoperability of real-world data and regional manufacturing investments continue to be decisive factors shaping where companies prioritize launches and scale production lines.

Corporate-level insights showing how product innovation, partnerships, and manufacturing resilience are being deployed to secure commercial and clinical differentiation

Leading companies in the osteoarthritis pain space are pursuing distinct but complementary strategies to preserve competitiveness and capture clinical differentiation. Many are investing in next-generation formulations that reduce systemic exposure while enhancing targeted exposure at the joint, thereby improving tolerability for older adults and patients with comorbidities. Strategic alliances across biotech developers, specialty pharmacies, and distribution partners are being used to accelerate market entry and to build longitudinal patient support services that enhance adherence and gather real-world outcomes data.

On the operational front, firms are strengthening sterile manufacturing capabilities and pursuing geographic diversification to reduce supply chain risk and better align with regional procurement trends. Commercially, there is a growing emphasis on value demonstration through health economic modeling and targeted outcomes studies designed to speak to institutional buyers and payers. Firms that combine clinical differentiation with transparent supply chain credentials and a clear pathway to demonstrate real-world impact are establishing clearer routes to premium positioning within clinical formularies and specialist prescribing environments.

Actionable recommendations for manufacturers and stakeholders to enhance supply resilience, clinical relevance, and payer-aligned value demonstration in osteoarthritis therapeutics

Industry leaders should adopt a multifaceted approach to sustain momentum and address near-term disruptions while building long-term competitive advantage. First, prioritize supplier diversification and invest in regional fill-finish and sterile production capacity to reduce exposure to cross-border trade volatility and to meet hospital procurement expectations for supply resilience. Second, align product development with pragmatic clinical needs by focusing on formulations that improve safety for older adults, enable outpatient administration, and reduce caregiver burden in home healthcare settings. Third, accelerate generation of real-world evidence that links drug performance to functional outcomes and health resource utilization to support payer conversations and outcomes-based contracts.

Further, companies should expand digital engagement and patient support infrastructure to improve adherence and to capture continuous outcomes data that can inform iterative product improvements. Commercial strategies should include targeted channel optimization to balance hospital pharmacy penetration with retail and online pharmacy access, ensuring that distribution meets both acute procedural demand and chronic maintenance needs. Finally, embed scenario planning into procurement and pricing strategies so that tariff changes, supply disruptions, or reimbursement shifts can be accommodated without compromising clinical supply or strategic launch timelines.

Clear explanation of the mixed-methods research approach integrating primary clinical insights, secondary intelligence, and scenario-based analysis to ensure rigorous and actionable findings

This research applied a mixed-methods approach combining primary stakeholder engagement, targeted secondary intelligence, and quantitative synthesis to ensure robust and actionable conclusions. Primary research included structured interviews with practicing rheumatologists, orthopedic surgeons, payers, hospital procurement leads, and senior commercial executives to capture therapeutic preferences, formulary dynamics, and procurement drivers. Secondary inputs were drawn from peer-reviewed clinical literature, regulatory publications, public clinical trial registries, patent filings, and validated supply chain databases to triangulate therapeutic trends, pipeline activity, and manufacturing footprints.

Analytic methods incorporated segmentation mapping, scenario analysis to explore supply disruption and tariff impacts, and cross-validation techniques to reconcile qualitative inputs with observed procurement behaviors. Quality assurance included expert review panels and methodological audits to confirm consistency of thematic findings. Together, these approaches produced a defensible evidence base that links clinical needs, distribution realities, and commercial imperatives to practical recommendations for product development and market access.

Conclusive synthesis of clinical, commercial, and operational imperatives that stakeholders must integrate to succeed in the evolving osteoarthritis therapeutic arena

In conclusion, the osteoarthritis pain drug environment is being reshaped by clinical innovation, distribution evolution, and supply chain imperatives that together define new commercial and clinical thresholds for success. Effective strategies will hinge on delivering differentiated clinical value through targeted formulations and delivery mechanisms, while simultaneously demonstrating real-world functional benefits that matter to payers and clinicians. Supply resilience, evidenced by regional manufacturing and transparent procurement practices, has become a nonnegotiable element of commercial credibility.

Stakeholders who align development portfolios with patient-centric outcomes, invest in evidence generation, and adopt flexible manufacturing and distribution models will be best positioned to navigate the evolving landscape. By integrating these strategic priorities into development and commercialization plans, organizations can better meet the diverse needs of clinicians and patients while maintaining operational agility in a dynamic regulatory and trade environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of subcutaneous monoclonal anti-NGF therapies showing improved pain relief durability in moderate to severe osteoarthritis
  • 5.2. Emergence of sustained release intra-articular hydrogel formulations extending therapeutic effects beyond twelve weeks for knee osteoarthritis
  • 5.3. Growing off-label use of low-dose oral cannabinoids supported by patient preference for alternative chronic osteoarthritis pain management
  • 5.4. Escalating investment in digital health platforms integrating wearable joint motion sensors with personalized pain management apps
  • 5.5. Increasing prevalence of biosimilar development targeting biosafety and cost reduction in anti-TNF therapies for osteoarthritis inflammation
  • 5.6. Implementation of real-world evidence studies evaluating comparative effectiveness of non-opioid analgesics in diverse osteoarthritis populations
  • 5.7. Expansion of combination therapies pairing NSAIDs with adjunctive nerve growth factor blockers to minimize gastrointestinal and cardiovascular risks

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Osteoarthritis Pain Drug Market, by Product Type

  • 8.1. Corticosteroids
  • 8.2. Cyclooxygenase 2 Inhibitors
  • 8.3. Nonsteroidal Anti-Inflammatory Drugs
  • 8.4. Symptomatic Slow Acting Drugs
  • 8.5. Viscosupplements

9. Osteoarthritis Pain Drug Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Intra Articular
    • 9.1.2. Intramuscular
  • 9.2. Oral
    • 9.2.1. Capsules
    • 9.2.2. Liquid
    • 9.2.3. Tablets
  • 9.3. Topical
    • 9.3.1. Cream
    • 9.3.2. Gel
    • 9.3.3. Patch

10. Osteoarthritis Pain Drug Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Osteoarthritis Pain Drug Market, by End User

  • 11.1. Clinics
  • 11.2. Home Healthcare
  • 11.3. Hospitals

12. Osteoarthritis Pain Drug Market, by Patient Age Group

  • 12.1. Adolescents Under 18
  • 12.2. Adults 18 64
  • 12.3. Elderly 65+

13. Osteoarthritis Pain Drug Market, by Disease Severity

  • 13.1. Mild
  • 13.2. Moderate
  • 13.3. Severe

14. Osteoarthritis Pain Drug Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Osteoarthritis Pain Drug Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Osteoarthritis Pain Drug Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Pfizer Inc.
    • 17.3.2. Novartis AG
    • 17.3.3. Bayer AG
    • 17.3.4. Johnson & Johnson
    • 17.3.5. Sanofi S.A.
    • 17.3.6. GlaxoSmithKline plc
    • 17.3.7. Viatris Inc.
    • 17.3.8. Teva Pharmaceutical Industries Ltd.
    • 17.3.9. Sandoz International GmbH
    • 17.3.10. Perrigo Company plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. OSTEOARTHRITIS PAIN DRUG MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. OSTEOARTHRITIS PAIN DRUG MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. OSTEOARTHRITIS PAIN DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CYCLOOXYGENASE 2 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CYCLOOXYGENASE 2 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CYCLOOXYGENASE 2 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CYCLOOXYGENASE 2 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CYCLOOXYGENASE 2 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CYCLOOXYGENASE 2 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SYMPTOMATIC SLOW ACTING DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SYMPTOMATIC SLOW ACTING DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SYMPTOMATIC SLOW ACTING DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SYMPTOMATIC SLOW ACTING DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SYMPTOMATIC SLOW ACTING DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SYMPTOMATIC SLOW ACTING DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY VISCOSUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY VISCOSUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY VISCOSUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY VISCOSUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY VISCOSUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY VISCOSUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INTRA ARTICULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INTRA ARTICULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INTRA ARTICULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INTRA ARTICULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INTRA ARTICULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INTRA ARTICULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY LIQUID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY LIQUID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY LIQUID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY LIQUID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CREAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CREAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CREAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CREAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CREAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CREAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY GEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY GEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY GEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY GEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY GEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY GEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ADOLESCENTS UNDER 18, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ADOLESCENTS UNDER 18, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ADOLESCENTS UNDER 18, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ADOLESCENTS UNDER 18, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ADOLESCENTS UNDER 18, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ADOLESCENTS UNDER 18, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ADULTS 18 64, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ADULTS 18 64, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ADULTS 18 64, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ADULTS 18 64, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ADULTS 18 64, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ADULTS 18 64, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ELDERLY 65+, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ELDERLY 65+, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ELDERLY 65+, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ELDERLY 65+, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ELDERLY 65+, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ELDERLY 65+, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MILD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MILD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MILD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MILD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MILD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MILD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MODERATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MODERATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MODERATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MODERATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MODERATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SEVERE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SEVERE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SEVERE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SEVERE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SEVERE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 298. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 302. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 304. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 310. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILL